巯基化羧甲基壳聚糖载醋甲唑胺纳米球滴眼剂的生物安全性评价  

Biological safety evaluation on thiolated carboxymethyl chitosan-carried methazolamide nanoparticle eye drop

作　　者：李光远[1,2] 娄建石[1] 陈斌[2] 李楠[2] 王晓辉[2] 刘佩莉[2] 祝君梅[2] LI Guang-yuan;LOU Jian-shi;CHEN Bin;LI Nan;WANG Xiao-hui;LIU Pei-li;ZHU Jun-mei(Department of Pharmacology,Tianjin Medical University,Tianjin 300070,China;Medical Biological Material Supervision and Research Center,Tianjin Institute of Medical and Pharmaceutical Sciences,Tianjin 300020,China)

机构地区：[1]天津医科大学药理学系,天津300070 [2]天津市医药科学研究所医用生物材料监测研究中心,天津300020

出　　处：《天津医科大学学报》2018年第4期298-301,共4页Journal of Tianjin Medical University

基　　金：天津市卫生局科技基金(青年)(2012KY34)

摘　　要：目的:研究巯基化羧甲基壳聚糖载醋甲唑胺纳米球滴眼剂的生物相容性。方法:以巯基化羧甲基壳聚糖为载体,包裹醋甲唑胺得到载药纳米球,制备成滴眼剂。采用迟发超敏试验、细胞毒性试验(MTT法和LDH法),对该滴眼剂进行生物安全性评价。结果:醋甲唑胺纳米球滴眼剂对豚鼠皮肤未出现红斑水肿现象,无致敏性,细胞毒性反应为2级,LDH释放率为37.09%,MTT试验和LDH试验IC50结果为0.24 g/m L和0.54 g/m L。结论:醋甲唑胺纳米球滴眼剂具有良好的生物相容性。Objective:To test the biological of thiolatedcarboxymethyl chitosan(tCMCS)-carried methazolamide(MTZ).Methods:This study used tCMCS as a drug carrier to prepare thiolatedcarboxymethyl chitosan-carried methazolamide nanoparticle eye drop(tCMCS-MTZ-NED).To measure the delayed-type hypersensitivity response,cytotoxicity test(MTT and LDH)of the tCMCS-MTZ-NED was performed.Results:tCMCS-MTZ-NED is not the sensitinogen for guinea pig(both integration and ratio of skin reaction are 0),cytotoxicity was grade 2,the release rate of LDH was 37.09%,the IC50 tested by refined MTT assay and LDH assay were 0.24 g/mL and 0.54 g/mL.Conclusion:tCMCS-MTZ-NED has good biocompatibility.

关 键 词：纳米球 醋甲唑胺 巯基化羧甲基壳聚糖 生物相容性 

分 类 号：R9[医药卫生—药学]